NCT05693142Phase 2, phase 3Active not recruiting

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-09Estimated

Enrollment · participants65Estimated

Source updated2026-07-21Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-21 · 2 fields changed

Primary completion date changed

− Before

~~Aug 2026~~

+ After

Sep 2026

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Posted 2026-06-30 · 1 field changed

Primary completion date changed

− Before

~~Feb 2026~~

+ After

Aug 2026

Check registry source

Study details

Conditions studied

Duchenne Muscular Dystrophy

Treatments or interventions studied

Not recorded

Primary outcomes · main study measures

Read the study measures

measure: Part 1 Safety measured by incidence of Adverse Events and Serious Adverse Events; description: Evaluate incidences of AEs and SAEs; timeFrame: 52 weeks; measure: Part 2 and 3 Pharmacodynamic; description: Proportion of participants whose RGX-202 microdystrophin protein expression determined in their muscle biopsy is ≥ 10% relative to dystrophin level in non-DMD participants; timeFrame: 12 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history